Targeted protein degradation experts Prof. Alessio Ciulli FRS and Dr Adam Gilbert appointed
SAB will provide strategic and scientific perspectives to support development of TRIMTAC and TRIMGLUE selective targeted protein degraders, and small molecule therapeutic pipeline
Cambridge, UK, 02 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB). Globally recognised leaders within the protein…
Members of the Industry Skills Accelerator (ISA) have celebrated a successful year of strengthening the UK’s medicines manufacturing workforce.
Launched in August 2024 and funded by Innovate UK, the ISA is a national initiative delivered through a partnership between Cogent Skills, the Cell and Gene Therapy Catapult (CGT Catapult), and CPI (part of the High Value Manufacturing Catapult).
Focused on advanced therapies and complex medicines – including cell, gene, vaccines, biologics, and other high-potential modalities such as mRNA and Oligonucleotides - the ISA is building targeted training…
LONDON, UK, and BOSTON, MA, September 2, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for AstriVax Therapeutics NV and is pleased to announce the placement of Dieter Weinand as Chair of its Board of Directors.AstriVax Therapeutics is a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary plug and play plasmid-based Launch-iT technology.US-based Dieter Weinand is the former Chief…
Appointment underscores Qureight’s commitment to drive adoption of its AI-powered imaging and clinical data curation platform to support clinical trials and accelerate drug development timelines for lung and heart diseases
Former big tech executive and NVIDIA director with proven track record of driving innovation in adoption of AI in life sciences and healthcare
Cambridge, UK, 01 September 2025 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced the…
The trend of staff redundancies and company down-sizing is prevalent in most if not all established life science ecosystems as reported in the recent “Biotech layoffs in 2025: The Labiotech tracker”. One Nucleus members are far from immune to this phenomenon being experienced of course and we see numerous examples of member employees finding themselves back in the jobs market. Mindful of the impact, One Nucleus strives to support both the redundant employees and the companies in the unfortunate position to be laying people off in order to maximise the chances of redeployment.…
Asymchem has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility.
SANDWICH, UNITED KINGDOM, August 2025 - Asymchem, a global leader in contract development and manufacturing (CDMO) solutions, has announced a significant expansion of its flow chemistry capabilities at Discovery Park, in Sandwich, UK. This milestone marks the first deployment of Asymchem’s proprietary and CE marking flow equipment in the Western market that further strengthens the company’s position in the adoption of advanced flow chemistry technologies.
The newly commissioned…
The August edition of our People Pathways newsletter is now available to read here!
Featuring:✅ One Nucleus upcoming courses✅ New Training Opportunities - We would love to hear from you on this!✅ Building Networks, Supporting Careers: Insights from Our AugustRoundtables✅ A One Nucleus Skills Exchange Forum on WhatsApp – Seeking Opinion✅ Details on the University of Cambridge Life Sciences Fair 2025✅ Cogent Skills Enabling Businesses to Take on Apprentices in Uncertain Times
Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolment
CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF
Cambridge, UK, 27 August 2025 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced that it has been selected by…
Sandwich, UK - 26 August 2025: Discovery Park, Kent’s leading hub for science and technology, today announced the arrival of two pioneering biotech companies to its innovation campus. iLoF (Intelligent Lab on Fiber), a digital health company and MilaK, a precision fermentation protein business, have now moved into their new laboratory space in Sandwich, Kent.
iLoF is on a mission to accelerate personalised drug development, by optimising clinical and pre-clinical drug development, beginning with a key focus on Alzheimer’s Disease. This impressive digital health company is leveraging…
Medicilon is pleased to announce the addition of comprehensive NAM (New Approach Methodologies) support to its drug R&D service platform. This is in line with the FDA's recent decision to undertake a phased-out approach to animal testing requirement for monoclonal antibodies and other biologic drugs, replacing it with in vitro models and technology. This decision officially incorporates NAMs, such as AI and organoids, into mainstream drug safety and efficacy assessment.
NAMs, including AI-driven simulations and advanced in vitro models, are transforming drug discovery and…